$SAGE
Sage Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024088593 Filed on July 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $11.87M $8.654M
YoY Change 337.08% 249.8%
Cost Of Revenue $5.278M $1.407M
YoY Change 486.44% 586.34%
Gross Profit $6.593M $7.247M
YoY Change 266.28% 219.39%
Gross Profit Margin 55.54% 83.74%
Selling, General & Admin $53.22M $55.98M
YoY Change -31.89% -25.91%
% of Gross Profit 807.2% 772.5%
Research & Development $54.58M $62.56M
YoY Change -46.45% -35.61%
% of Gross Profit 827.79% 863.31%
Depreciation & Amortization $255.0K $311.0K
YoY Change -15.0% -6.04%
% of Gross Profit 3.87% 4.29%
Operating Expenses $113.1M $120.0M
YoY Change -47.3% -30.55%
Operating Profit -$101.2M -$111.3M
YoY Change -52.23% -34.7%
Interest Expense $7.642M $8.431M
YoY Change -25.62% -17.12%
% of Operating Profit
Other Income/Expense, Net $9.000K $15.00K
YoY Change -116.36% -136.59%
Pretax Income -$93.55M -$102.9M
YoY Change -53.6% -35.85%
Income Tax
% Of Pretax Income
Net Earnings -$93.55M -$102.9M
YoY Change -53.6% -35.85%
Net Earnings / Revenue -788.06% -1188.51%
Basic Earnings Per Share -$1.53 -$1.70
Diluted Earnings Per Share -$1.53 -$1.70
COMMON SHARES
Basic Shares Outstanding 61.05M 60.18M
Diluted Shares Outstanding 61.12M 60.54M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $569.2M $646.8M
YoY Change -35.03% -35.49%
Cash & Equivalents $99.63M $99.90M
Short-Term Investments $469.5M $546.9M
Other Short-Term Assets $17.76M $26.28M
YoY Change -48.81% -43.28%
Inventory
Prepaid Expenses
Receivables $14.87M $9.943M
Other Receivables $0.00 $0.00
Total Short-Term Assets $605.0M $686.8M
YoY Change -35.18% -35.45%
LONG-TERM ASSETS
Property, Plant & Equipment $1.019M $1.274M
YoY Change -58.27% -87.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.175M $7.800M
YoY Change -21.51% -5.12%
Total Long-Term Assets $17.45M $10.29M
YoY Change 6.42% -43.63%
TOTAL ASSETS
Total Short-Term Assets $605.0M $686.8M
Total Long-Term Assets $17.45M $10.29M
Total Assets $622.4M $697.1M
YoY Change -34.46% -35.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.126M $8.650M
YoY Change -36.01% -6.82%
Accrued Expenses $53.20M $58.98M
YoY Change -53.7% 112.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.41M $69.04M
YoY Change -54.58% -28.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.19M
YoY Change
Total Long-Term Liabilities $10.19M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.41M $69.04M
Total Long-Term Liabilities $10.19M $0.00
Total Liabilities $70.60M $69.04M
YoY Change -46.92% -29.48%
SHAREHOLDERS EQUITY
Retained Earnings -$2.875B -$2.781B
YoY Change 13.31% 19.08%
Common Stock $3.426B $3.410B
YoY Change 2.03% 2.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $551.8M $628.1M
YoY Change
Total Liabilities & Shareholders Equity $622.4M $697.1M
YoY Change -34.46% -35.59%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$93.55M -$102.9M
YoY Change -53.6% -35.85%
Depreciation, Depletion And Amortization $255.0K $311.0K
YoY Change -15.0% -6.04%
Cash From Operating Activities -$82.36M -$80.44M
YoY Change -39.39% -38.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $81.05M -$386.0K
YoY Change -49.56% -100.84%
Cash From Investing Activities $81.05M -$386.0K
YoY Change -49.47% -100.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.037M 8.071M
YoY Change -62.96% 852.89%
NET CHANGE
Cash From Operating Activities -82.36M -80.44M
Cash From Investing Activities 81.05M -386.0K
Cash From Financing Activities 1.037M 8.071M
Net Change In Cash -274.0K -72.75M
YoY Change -101.0% -14.49%
FREE CASH FLOW
Cash From Operating Activities -$82.36M -$80.44M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$82.36M -$80.44M
YoY Change -39.57% -38.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36544
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
dei Entity Address Address Line1
EntityAddressAddressLine1
215 First Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
299-8380
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SAGE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61050418
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99901000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70992000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
546892000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
682192000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
28743000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31825000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9943000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83009000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
686811000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
869350000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1274000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1921000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1220000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4458000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7800000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6548000
CY2024Q2 us-gaap Assets
Assets
697105000
CY2023Q4 us-gaap Assets
Assets
882277000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8650000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10318000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58982000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1411000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5165000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
69043000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82747000
CY2024Q2 us-gaap Liabilities
Liabilities
69043000
CY2023Q4 us-gaap Liabilities
Liabilities
82747000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60897967
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60046676
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60894934
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60043643
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3410143000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3370397000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2780996000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2569659000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-691000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-814000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
628062000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
697105000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
882277000
CY2024Q2 us-gaap Revenues
Revenues
8654000
CY2023Q2 us-gaap Revenues
Revenues
2474000
us-gaap Revenues
Revenues
16556000
us-gaap Revenues
Revenues
5768000
CY2024Q2 sage Cost Of Revenues
CostOfRevenues
1407000
CY2023Q2 sage Cost Of Revenues
CostOfRevenues
205000
sage Cost Of Revenues
CostOfRevenues
2676000
sage Cost Of Revenues
CostOfRevenues
435000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62564000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97161000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
134297000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
189987000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55983000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75565000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
108556000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
141273000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
119954000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
172931000
us-gaap Operating Expenses
OperatingExpenses
245529000
us-gaap Operating Expenses
OperatingExpenses
331695000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-111300000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-170457000
us-gaap Operating Income Loss
OperatingIncomeLoss
-228973000
us-gaap Operating Income Loss
OperatingIncomeLoss
-325927000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8431000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10173000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
17634000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
19003000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-229000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
us-gaap Net Income Loss
NetIncomeLoss
-211337000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.7
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.7
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.14
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60538319
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60538319
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59769640
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59769640
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60337258
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60337258
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59722147
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59722147
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
us-gaap Net Income Loss
NetIncomeLoss
-211337000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
96000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-556000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
123000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4562000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-102758000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160881000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-211214000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-302591000
us-gaap Profit Loss
ProfitLoss
-211337000
us-gaap Profit Loss
ProfitLoss
-307153000
us-gaap Share Based Compensation
ShareBasedCompensation
30865000
us-gaap Share Based Compensation
ShareBasedCompensation
31731000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
135000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
71000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3491000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
7570000
us-gaap Depreciation
Depreciation
647000
us-gaap Depreciation
Depreciation
654000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3082000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4505000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-73066000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1430000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-248000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2119000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-3238000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2972000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-3754000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
82000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
0
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-3488000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1668000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9566000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9030000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6253000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118269000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-285200000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
398986000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
630452000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
259936000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
389655000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
337000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
139050000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
240460000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1585000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4156000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
8163000
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
637000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9628000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3519000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30409000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41221000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72324000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163969000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102733000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122748000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2863000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19568000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5118000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-629000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-146828000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1133129000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11281000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-556000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-8000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1507000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13170000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
27000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-2000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-108483000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
705801000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16947000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8047000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
628062000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
98874000
CY2024Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
546892000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
645766000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
68547000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
682192000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
750739000
CY2024Q2 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2023Q2 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
547583000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
25000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
716000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
546892000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
683006000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
437000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1251000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
682192000
CY2024Q2 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2023Q2 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
322255000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
432000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
101647000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
284000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
423902000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
716000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
343373000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
611000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
123121000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
640000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
466494000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1251000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q2 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
33753000
CY2023Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
26040000
CY2024Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
762000
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
10589000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14297000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21339000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9726000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8589000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
444000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
707000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58982000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q2 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3033
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
40300000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17167000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11693000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30865000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31731000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17167000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11693000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30865000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31731000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.41
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
us-gaap Net Income Loss
NetIncomeLoss
-211337000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60538319
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60538319
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59769640
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59769640
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60337258
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60337258
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59722147
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59722147
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.7
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.7
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.14
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9049840
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8385284
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9049840
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8385284
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
32800000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
10589000
us-gaap Restructuring Charges
RestructuringCharges
597000
us-gaap Payments For Restructuring
PaymentsForRestructuring
9230000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
762000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-088593-index-headers.html Edgar Link pending
0000950170-24-088593-index.html Edgar Link pending
0000950170-24-088593.txt Edgar Link pending
0000950170-24-088593-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img94125284_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20240630.htm Edgar Link pending
sage-20240630.xsd Edgar Link pending
sage-ex10_1.htm Edgar Link pending
sage-ex10_2.htm Edgar Link pending
sage-ex10_3.htm Edgar Link pending
sage-ex10_4.htm Edgar Link pending
sage-ex10_5.htm Edgar Link pending
sage-ex10_6.htm Edgar Link pending
sage-ex31_1.htm Edgar Link pending
sage-ex31_2.htm Edgar Link pending
sage-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
sage-20240630_htm.xml Edgar Link completed